"Designing Growth Strategies is in our DNA"
Brain ischemia is the condition where, there is lack of adequate supply to the brain in order to perform metabolic activities. Brain ischemia is also referred as cerebral ischemia or cerebrovascular ischemia. Additionally, Thrombotic, Embolic and Hypoperfusion are the commonly observed types of brain ischemia. One sided body weakness, confusion or disorientation, dizziness, double vision, and slurred speech are some of the commonly observed symptoms of brain ischemia amongst others. The disease is prominently caused due to sickle cell anaemia, heart disease, blood clots, and congenital heart diseases. According to study conducted by American Heart Association in 2017, an estimated 300,000 people suffers from traumatic brain injury each year in the U.S.
At present, the brain ischemia treatment includes lifestyle change, routine exercise, and stress management. Moreover, certain drugs such as anti-platelet drugs and anticoagulants are prescribed by physicians to treat brain ischemia.
Pharmaceutical companies and academic centers & research institutes are prominently focusing on studying and developing new treatment options for the Brain ischemia. For instance; BMS-986177, which is being studied by Bristol-Myers Squibb, is currently in phase-2 clinical trials to check its efficacy and tolerability for the prevention of new ischemic stroke in patients with transient ischemic attack.
At present around 61% of the pipeline candidates for Brain ischemia are in the phase-2 and phase-3 stage. Majority of the studies have been sponsored by pharmaceutical companies and research institutes & academic centres.
The report on ‘Brain Ischemia – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Brain Ischemia. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Brain Ischemia.
The report on ‘Brain Ischemia – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players